
Is TECH (Bio-Techne Corporation) Halal or Haram?
Bio-Techne Corporation comfortably passes all AAOIFI shariah screening criteria with exceptional financial purity. The company maintains a very conservative debt-to-market cap ratio of 5.3%, well below the 33% threshold, and generates a negligible 0.32% of its revenue from interest-bearing activities. With cash and securities at just 1.9% of its market cap, TECH represents a robust, fully compliant biotechnology option for halal portfolios.
Price Chart (5D)
TECH — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2026-05-01 | 55.08 | 55.64 | 53.58 | 55.02 | 2.0M | -0.11% |
| 2026-04-30 | 52.42 | 55.93 | 51.90 | 55.32 | 3.5M | +5.53% |
| 2026-04-29 | 53.04 | 53.74 | 51.03 | 51.95 | 1.4M | -2.06% |
| 2026-04-28 | 55.00 | 55.29 | 52.99 | 53.51 | 1.6M | -2.71% |
| 2026-04-27 | 54.29 | 55.50 | 53.77 | 55.11 | 1.5M | +1.51% |
| 2026-04-24 | 52.53 | 54.74 | 52.05 | 54.19 | 2.0M | +3.16% |
| 2026-04-23 | 57.52 | 57.57 | 51.13 | 52.20 | 3.3M | -9.25% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for TECH
Business Activity
Permissible
Bio-Techne Corporation's business of developing life science reagents, clinical diagnostics, and cell therapy technologies is permissible and aligns with Islamic principles of promoting health and scientific advancement.
Debt / Market Cap
5.30%
Interest Income
0.32%
Cash & Securities
1.94%
About Bio-Techne Corporation (TECH)
Bio-Techne Corporation is a key player in the biotechnology sector, specializing in life science reagents, instruments, and clinical diagnostic services. The company primarily operates through its Protein Sciences and Diagnostics and Genomics segments, providing essential tools like cytokines, antibodies, and cell selection technologies used in cutting-edge research and gene therapy.
For Muslim investors, Bio-Techne represents a strong Halal investment opportunity, having successfully passed all AAOIFI screening criteria. The company's core operations in healthcare and scientific research are highly beneficial and fully permissible, ensuring your investment supports ethical, life-saving advancements without engaging in prohibited industries.
From an Islamic finance perspective, Bio-Techne's financial structure is exceptionally clean. The company boasts a remarkably low debt-to-market cap ratio of just 5.3%, alongside minimal interest income representing only 0.32% of total revenue, meaning investors do not have to worry about excessive leverage or non-permissible earnings.
While there are no current scholarly debates regarding Bio-Techne's compliance, halal investors should continue to monitor its future acquisitions. As the company expands its diagnostics and genomics portfolio, ensuring new subsidiaries maintain this strict financial purity will be key to long-term shariah compliance.
CEO
Kim Kelderman
Employees
3,100
IPO Date
1989-02-09
Headquarters
Minneapolis, MN, US
Website
www.bio-techne.comTECH Key Financial Statistics
Revenue
$1.22B
Net Income
$73.4M
EPS (Diluted)
$0.46
Stock Price
53.51
Beta
1.49
52-Week Range
46.05-72.16
Total Debt
$444.1M
Total Equity
$1.92B
Current Ratio
3.46
TECH Financial Health & Profitability
Profit Margins
Revenue Growth (YoY)
+5.2%
Prior year: $1.16B
Net Debt
$281.9M
Cash: $162.2M — Debt: $444.1M
R&D Spending
$99.5M
% of Revenue
8.2%
Frequently Asked Questions About TECH
Is TECH (Bio-Techne Corporation) stock halal to invest in?▾
What does Bio-Techne Corporation do?▾
What screening criteria were used for TECH?▾
Does TECH require income purification?▾
When was TECH last screened?▾
Disclaimer
This shariah compliance assessment for TECH (Bio-Techne Corporation) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.